These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22358305)

  • 1. Ingenol mebutate: an introduction.
    Fallen RS; Gooderham M
    Skin Therapy Lett; 2012 Feb; 17(2):1-3. PubMed ID: 22358305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
    Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
    Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
    Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
    J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ingenol mebutate (Picato) for actinic keratosis.
    Med Lett Drugs Ther; 2012 Apr; 54(1389):35-6. PubMed ID: 22538622
    [No Abstract]   [Full Text] [Related]  

  • 5. Ingenol mebutate gel for actinic keratosis.
    Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
    N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermoscopic monitoring of efficacy of ingenol mebutate in the treatment of pigmented and non-pigmented basal cell carcinomas.
    Diluvio L; Bavetta M; Di Prete M; Orlandi A; Bianchi L; Campione E
    Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27860083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
    Berman B
    Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superficial basal cell carcinoma successfully treated with ingenol mebutate gel 0.05%.
    Cantisani C; Paolino G; Cantoresi F; Faina V; Richetta AG; Calvieri S
    Dermatol Ther; 2014; 27(6):352-4. PubMed ID: 25052730
    [No Abstract]   [Full Text] [Related]  

  • 9. Ingenol mebutate: potential for further development of cancer immunotherapy.
    Doan HQ; Gulati N; Levis WR
    J Drugs Dermatol; 2012 Oct; 11(10):1156-7. PubMed ID: 23134979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial.
    Siller G; Rosen R; Freeman M; Welburn P; Katsamas J; Ogbourne SM
    Australas J Dermatol; 2010 May; 51(2):99-105. PubMed ID: 20546215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).
    Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F
    Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PICATO (ingenol mebutate 0.015% and 0.05% gels): a novel treatment for actinic keratosis.
    Abramovits W; Oquendo M; Vincent KD; Gupta AK
    Skinmed; 2013; 11(2):111-5. PubMed ID: 23745230
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses.
    Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK
    JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ingenol mebutate: a new option for actinic keratosis treatment.
    Gras J
    Drugs Today (Barc); 2013 Jan; 49(1):15-22. PubMed ID: 23362492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice.
    Bettencourt MS
    J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
    Gupta AK; Paquet M
    J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ingenol mebutate for pigmented superficial basal cell carcinomas: evaluation by confocal microscopy.
    Monfrecola G; Scalvenzi M; Costa C; Cantelli M; Fabbrocini G
    G Ital Dermatol Venereol; 2019 Oct; 154(5):586-588. PubMed ID: 27284778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rapidly growing squamous cell carcinoma after ingenol mebutate treatment].
    Ehret M; Velter C; Tebacher M; Bruant-Rodier C; Cribier B
    Ann Dermatol Venereol; 2018 Oct; 145(10):607-612. PubMed ID: 29779859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
    Keating GM
    Drugs; 2012 Dec; 72(18):2397-405. PubMed ID: 23231025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.
    Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Goncalves J; Larsson T; Skov T; Swanson N
    J Drugs Dermatol; 2014 Feb; 13(2):154-60. PubMed ID: 24509965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.